Abstract: TH-PO079
A Tertiary Care Centre Experience of COVID-19-Associated AKI During the First and Second Waves of the Pandemic
Session Information
- AKI: Biomarkers, Risk Factors, Treatments, Outcomes
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical‚ Outcomes‚ and Trials
Authors
- Kumaresan, Maithrayie, University Hospital Lewisham, London, London, United Kingdom
- Mogga, Phanidhar, MGM Healthcare, Chennai, Tamilnadu, India
- Abraham, Georgi, MGM Healthcare, Chennai, Tamilnadu, India
- Rajagopalan, Urjitha, MGM Healthcare, Chennai, Tamilnadu, India
Background
There is a scarcity of information on the incidence and outcomes of acute kidney injury in COVID-19 patients in India. Therefore, we analysed the correlation of AKI risk factors and compared the outcomes of the first and second COVID-19 waves in a tertiary care centre.
Methods
●Single centre retrospective analysis
●Patients who tested positive for COVID-19 between July 2020 and May 2021, with serum creatinine levels measured on admission (n= 1260).
●AKI was defined according to the KDIGO clinical practice guidelines.
●Multivariate binomial logistic regression yielded odds ratios for risk variables of AKI.
●Age-adjusted odds ratios(OR) were used to compare COVID-19 outcomes between the first and second waves.
Results
Baseline characteristics:
●Median Age= 56 (IQR 47-66)
●Population with diabetes-55.2%
●Population with hypertension-42.11%
All AKI (n=86)
●Stage 1 (n=57)
●Stage 2 (n=20)
●Stage 3 (n=9)
Risk factors for AKI:
●Diabetes OR 1.9 (1.2 – 3.1)
●Hypertension OR 3.2 (2.0 – 5.2)
●C-reactive protein ≥ 10 mg/dl, OR 3.6 (1.6 – 8.0).
●D-dimer ≥ 250 pg/ml, OR 4.2 (2.5 – 6.8).
●Need for ventilation OR 3.06 (1.8 – 4.9)
Comparison of COVID -19 outcomes:
Compared to the first wave, the second wave cohort had lower risk for:
●Acute kidney injury (adj OR: 0.4; CI: 0.2-0.7)
●Mortality (adj OR: 0.2; CI: 0.09-0.7)
●Invasive mechanical ventilation (adj OR: 0.2; CI: 0.06 - 0.8)
●Length of ICU stay > 5days (adj OR: 0.4; CI: 0.2 - 0.7)
Conclusion
In our retrospective study, AKI prevalence was 6.8%, and the mortality rate of 2.9%. Our analysis shows that the second wave of COVID -19 exhibits improved clinical outcomes compared to the first wave